Taysha Gene Therapies (NASDAQ:TSHA – Get Free Report) had its target price boosted by stock analysts at Cantor Fitzgerald from $6.00 to $7.00 in a research report issued to clients and investors on Wednesday, Benzinga reports. The firm currently has an “overweight” rating on the stock. Cantor Fitzgerald’s price target indicates a potential upside of 345.86% from the company’s previous close.
Other equities research analysts have also issued research reports about the stock. JMP Securities reissued a “market outperform” rating and issued a $4.00 price objective on shares of Taysha Gene Therapies in a research report on Tuesday, August 15th. Robert W. Baird increased their price objective on shares of Taysha Gene Therapies from $6.00 to $8.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 15th. Chardan Capital reissued a “buy” rating and issued a $5.00 price objective on shares of Taysha Gene Therapies in a research report on Tuesday, August 15th. Canaccord Genuity Group dropped their price objective on shares of Taysha Gene Therapies from $7.00 to $6.00 and set a “buy” rating for the company in a research report on Wednesday, September 20th. Finally, Truist Financial dropped their price objective on shares of Taysha Gene Therapies from $6.00 to $5.00 and set a “buy” rating for the company in a research report on Wednesday, September 20th. Three research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $5.89.
Taysha Gene Therapies Stock Performance
Taysha Gene Therapies (NASDAQ:TSHA – Get Free Report) last issued its quarterly earnings results on Monday, August 14th. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.07). The company had revenue of $2.40 million for the quarter, compared to analysts’ expectations of $2.00 million. As a group, equities analysts forecast that Taysha Gene Therapies will post -0.71 EPS for the current fiscal year.
Insider Activity at Taysha Gene Therapies
In related news, CFO Kamran Alam sold 33,000 shares of the firm’s stock in a transaction on Thursday, August 24th. The shares were sold at an average price of $2.33, for a total transaction of $76,890.00. Following the completion of the sale, the chief financial officer now directly owns 258,042 shares of the company’s stock, valued at approximately $601,237.86. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 2.25% of the company’s stock.
Institutional Inflows and Outflows
Large investors have recently added to or reduced their stakes in the stock. Dynamic Advisor Solutions LLC bought a new position in Taysha Gene Therapies during the 2nd quarter valued at $30,000. Virtu Financial LLC bought a new position in Taysha Gene Therapies during the 1st quarter valued at $36,000. Quantum Private Wealth LLC boosted its stake in Taysha Gene Therapies by 40.4% during the 2nd quarter. Quantum Private Wealth LLC now owns 504,380 shares of the company’s stock valued at $333,000 after acquiring an additional 145,013 shares during the last quarter. FMR LLC boosted its stake in Taysha Gene Therapies by 2,035.0% during the 3rd quarter. FMR LLC now owns 24,527,801 shares of the company’s stock valued at $77,508,000 after acquiring an additional 23,378,974 shares during the last quarter. Finally, EAM Investors LLC bought a new position in Taysha Gene Therapies during the 3rd quarter valued at $1,060,000. 25.91% of the stock is currently owned by institutional investors.
About Taysha Gene Therapies
Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis.
- Five stocks we like better than Taysha Gene Therapies
- Best Stocks Under $5.00
- Amazon, Target, Walmart in a race for fastest delivery
- What is a Stock Market Index and How Do You Use Them?
- Palo Alto Networks: the one security stock to rule them all
- How to Invest in Blue Chip Stocks
- Is it time to buy the dip in Walmart shares?
Receive News & Ratings for Taysha Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taysha Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.